Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05463848 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05463848 · ClinicalTrials.gov record · last posted 2026-08-24

Surgical Pembro +/- Olaparib w TMZ for rGBM

Name: Surgical Pembro +/- Olaparib w TMZ for rGBM — clinical trial record (NCT05463848)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorL. Nicolas Gonzalez Castro, MD, PhD

Started2022-10-21

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Temodar)

Protocol amendment history 4 changes detected by DataLookout

2026-08-25

Enrollment closed, study ongoing

2026-08-25

Primary endpoint(s) modified

Was6-month Progression-Free Survival (PFS6)~~, Tumor infiltrating lymphocytes (TIL) Density~~

Now6-month Progression-Free Survival (PFS6)

2026-08-25

Enrollment reduced: 78 → 52 participants

2026-08-25

Primary completion moved earlier: 2026-08-01 → 2026-05-19

Trial Details

NCT Number	NCT05463848
Lead Sponsor	L. Nicolas Gonzalez Castro, MD, PhD Collaborators: Merck Sharp & Dohme LLC
Conditions	Glioblastoma, Recurrent Glioblastoma
Enrollment	52 participants
Start Date	2022-10-21
Primary Completion	2026-05-19 (estimated)
Study Completion	2027-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-24